Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA3 | P07451 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | CA5A | P35218 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571327 | 1.00 | CA12 (0.55) | CA12CA1CA2CA3CA4 | |
| SCHEMBL23783264 | 0.91 | CA12 (0.50) | CA12CA1CA2CA3CA4 | |
| SCHEMBL6858908 | 0.86 | CA12 (0.50) | CA12CA1CA2CA3CA4 | |
| SCHEMBL17239530 | 0.86 | LCK (0.48) | CA12CA1CA2CA3CA4 | |
| SCHEMBL69107 | 0.83 | CA1 (0.59) | CA12CA1CA2CA3CA4 | |
| SCHEMBL18920510 | 0.83 | CA1 (0.52) | CA12CA1CA2CA3CA4 | |
| SCHEMBL3337006 | 0.83 | CA1 (0.53) | CA12CA1CA2CA3CA4 | |
| SCHEMBL31497643 | 0.83 | CA1 (0.53) | CA12CA1CA2CA3CA4 | |
| SCHEMBL8678983 | 0.82 | CA1 (0.52) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1552250 | 0.81 | CA12 (0.46) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024240840-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | BEACTICA THERAPEUTICS AB (SE) | 2024-11-28 | — | — | WO | disclosed |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4364737-A2 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4229056-B1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-04 | — | — | US | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116802181-A | Triazolopyridine compounds as kinase inhibitors | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-04-26 | — | — | US | disclosed |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-04-26 | — | — | US | disclosed |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-04-26 | — | — | US | disclosed |
| WO-2011159067-A2 | THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2011-12-22 | — | — | WO | disclosed |
| WO-2010147430-A2 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147430-A2 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, SLC10A2 | CA12 3434/4885CA1 4050/4885CA2 530/4885 |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | CA12 2728/4885CA1 4097/4885CA2 526/4885 |
| US-20220119388-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | CA12 4877/4885CA1 4813/4885CA2 3856/4885 |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | CA12 4877/4885CA1 4813/4885CA2 3856/4885 |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | CA12 4877/4885CA1 4813/4885CA2 3856/4885 |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | CA12 4877/4885CA1 4813/4885CA2 3856/4885 |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | CA12 4877/4885CA1 4813/4885CA2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.